Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1309-1318

  Yang, Tianzhi ^a   Nyiawung, Divine ^a   Silber, Alexandra ^a   Hao, Jiukuan ^b   Lai, Leanne ^c   Bai, Shuhua ^a  

^a HUSSON UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

chitosan; low molecular weight heparin; nanoparticles; PLGA

Indexed keywords

CHITOSAN; LOW MOLECULAR WEIGHT HEPARIN; MICROSPHERE; NANOPARTICLE; POLYELECTROLYTE; POLYGLACTIN;

ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; COMPLEX FORMATION; DIFFUSION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; EVAPORATION; FEASIBILITY STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFRARED SPECTROSCOPY; LUNG ALVEOLUS EPITHELIUM; NANOEMULSION; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

CELL LINE; CELL SURVIVAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; EPITHELIAL CELLS; FEASIBILITY STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID;

EID: 84871653827     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9854-8     Document Type: Article

References (43)

1. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771-82. doi: 10.1038/nrd2614.
2. Tan ML, Choong PF, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol. 2009;61:3-12. doi: 10.1211/jpp/61.01.0002.
3. Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv. 2004;12:41-57. doi: 10.1080/10717540590889781.
4. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12-27. doi: 10.1016/j.addr.2009.08.004.
5. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17:247-89.
6. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125:193-209. doi: 10.1016/j.jconrel.2007.09.013.
7. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57:171-85.
8. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm. 1999;25:471-6. doi: 10.1081/DDC-100102197.
9. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18:1315-9.
10. Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol. 2006;215:100-8. doi: 10.1016/j.taap.2006.01.016.
11. Katas H, Cevher E, Alpar HO. Preparation of polyethyleneimine incorporated poly(d,l-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Int J Pharm. 2009;369:144-54. doi: 10.1016/j.ijpharm.2008.10.012.
12. Taetz S, Nafee N, Beisner J, Piotrowska K, Baldes C, Murdter TE, et al. The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells. Eur J Pharm Biopharm. 2009;72:358-69. doi: 10.1016/j.ejpb.2008.07.011.
13. Ungaro F, di Villa d'Emmanuele BR, Giovino C, Miro A, Sorrentino R, Quaglia F, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release. 2009;135:25-34. doi: 10.1016/j.jconrel.2008.12.011.
14. Amoozgar Z, Park J, Lin Q, Yeo Y. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm. 2012;9(5):1262-70. doi: 10.1021/mp2005615.
15. Hou Y, Hu J, Park H, Lee M. Chitosan-based nanoparticles as a sustained protein release carrier for tissue engineering applications. J Biomed Mater Res A. 2012;100:939-47. doi: 10.1002/jbm.a.34031.
16. Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci. 2012;45:632-8. doi: 10.1016/j.ejps.2012.01.002.
17. Nandagiri VK, Gentile P, Chiono V, Tonda-Turo C, Matsiko A, Ramtoola Z, et al. Incorporation of PLGA nanoparticles into porous chitosan-gelatin scaffolds: influence on the physical properties and cell behavior. J Mech Behav Biomed Mater. 2011;4:1318-27. doi: 10.1016/j.jmbbm.2011.04.019.
18. Zeng P, Xu Y, Zeng C, Ren H, Peng M. Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm. 2011;415:259-66. doi: 10.1016/j.ijpharm.2011.05. 053.
19. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol. 1998;82:3L-10L.
20. Kleinschmidt K, Charles R. Pharmacology of low molecular weight heparins. Emerg Med Clin North Am. 2001;19:1025-49.
21. Bai S, Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res. 2009;26:539-48. doi: 10.1007/s11095-008-9769-y.
22. Bai S, Ahsan F. Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J Pharm Sci. 2010;99:4554-64. doi: 10.1002/jps.22160.
23. Bai S, Gupta V, Ahsan F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. Eur J Pharm Sci. 2009;38:165-71. doi: 10.1016/j.ejps.2009.07.002.
24. Bai S, Gupta V, Ahsan F. Inhalable lactose-based dry powder formulations of low molecular weight heparin. J Aerosol Med Pulm Drug Deliv. 2010;23:97-104. doi: 10.1089/jamp.2009.0745.
25. Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci. 2007;96:2090-106. doi: 10.1002/jps.20849.
26. Yang T, Hussain A, Bai S, Khalil IA, Harashima H, Ahsan F. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. J Control Release. 2006;115:289-97. doi: 10.1016/j.jconrel.2006.08.015.
27. Yang T, Mustafa F, Bai S, Ahsan F. Pulmonary delivery of low molecular weight heparins. Pharm Res. 2004;21:2009-16.
28. Paliwal R, Paliwal SR, Agrawal GP, Vyas SP. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: in vitro and in vivo evaluation. Int J Pharm. 2012;422:179-84. doi: 10.1016/j.ijpharm.2011.10.048.
29. He J, Zhou Z, Fan Y, Zhou X, Du H. Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method. J Microencapsul. 2011;28:763-70. doi: 10.3109/02652048.2011. 629740.
30. Thomas C, Gupta V, Ahsan F. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res. 2010;27:905-19. doi: 10.1007/s11095-010-0094-x.
31. Sun W, Mao S, Mei D, Kissel T. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin. Eur J Pharm Biopharm. 2008;69:417-25. doi: 10.1016/j.ejpb.2008.01.016.
32. Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release. 2008;128:224-32. doi: 10.1016/j.jconrel.2008.03.013.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
34. Markovich RJ, Pidgeon C. Introduction to Fourier transform infrared spectroscopy and applications in the pharmaceutical sciences. Pharm Res. 1991;8:663-75.
35. Kaur G, Rana V, Jain S, Tiwary AK. Colon delivery of budesonide: evaluation of chitosan-chondroitin sulfate interpolymer complex. AAPS PharmSciTech. 2010;11:36-45. doi: 10.1208/s12249-009-9353-8.
36. Liu Z, Jiao Y, Liu F, Zhang Z. Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation. J Biomed Mater Res A. 2007;83:806-12. doi: 10.1002/jbm.a.31407.
37. Ravi Kumar MNV, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771-7. doi: 10.1016/j.biomaterials.2003.08.069.
38. Awotwe-Otoo D, Zidan AS, Rahman Z, Habib MJ. Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies. AAPS PharmSciTech. 2012;13:611-22. doi: 10.1208/s12249-012-9782-7.
39. Braun CS, Vetro JA, Tomalia DA, Koe GS, Koe JG, Middaugh CR. Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J Pharm Sci. 2005;94:423-36.
40. Wilhelm P, Stephan D. On-line tracking of the coating of nanoscaled silica with titania nanoparticles via zeta-potential measurements. J Colloid Interface Sci. 2006;293:88-92. doi: 10.1016/j.jcis.2005.06.047.
41. Yang R, Yang SG, Shim WS, Cui F, Cheng G, Kim IW, et al. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci. 2009;98:970-84. doi: 10.1002/jps.21487.
42. Wu J, Ding D, Ren G, Xu X, Yin X, Hu Y. Sustained delivery of endostatin improves the efficacy of therapy in Lewis lung cancer model. J Control Release. 2009;134:91-7. doi: 10.1016/j.jconrel.2008.11.004.
43. Nair KL, Jagadeeshan S, Nair SA, Kumar GS. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomed. 2011;6:1685-97. doi: 10.2147/IJN.S20165.